Insights derived from real-world data are changing every facet of pharma but its impact on clinical trials may prove to be a crowning achiev...
The potential benefits of moving to a variable pricing model based on indication are manifold, but is the US healthcare system ready?
One year on, Brent Saunders of Allergan suggests to Paul Simms the case for expanding the pharma-patient social contract across the industry
In digital, it’s all about personalization. Isn’t it time pharma caught up with other industries?